Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Tseng, Chin Hsiao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Breast cancer; Human insulin; Incidence; Taiwan; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HUMAN INSULIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ANTIDIABETIC AGENT; ISOPHANE INSULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; TAIWANESE; TREATMENT DURATION; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; INCIDENCE; MULTICENTER STUDY; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN;

BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; ISOPHANE INSULIN, HUMAN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN;

EID: 84947025949     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1876-7     Document Type: Article

References (46)

1. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121:856-62.
2. Tseng CH, Chong CK, Tai TY. Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Diabetologia. 2009;52:240-6.
3. Radulescu RT. Intracellular insulin in human tumors: examples and implications. Diabetol Metab Syndr. 2011;3:5.
4. Dool CJ, Mashhedi H, Zakikhani M, David S, Zhao Y, Birman E, et al. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocr Relat Cancer. 2011;18:699-709.
5. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer. 2010;17:941-51.
6. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 2009;125:2704-10.
7. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999-1005.
8. Call R, Grimsley M, Cadwallader L, Cialone L, Hill M, Hreish V, et al. Insulin--carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad Med. 2010;122:158-65.
9. Teng JA, Hou RL, Li DL, Yang RP, Qin J. Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res. 2011;43:519-23.
10. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010;33:1997-2003.
11. Suissa S, Azoulay L, Dell'aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. 2011;54:2254-62.
12. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012;55:51-62.
13. Lind M, Fahlén M, Eliasson B, Odén A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes. 2012;6:53-9.
14. Wilson C. Diabetes: long-term use of insulin glargine might increase the risk of breast cancer. Nat Rev Endocrinol. 2011;7:499.
15. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35:278-80.
16. Tseng CH. Rosiglitazone is not associated with an increased risk of bladder cancer. Cancer Epidemiol. 2013;37:385-9.
17. Tseng CH. Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan. Diabetologia. 2011;54:2009-15.
18. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33:1304-8.
19. Tseng CH. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. Breast Cancer Res Treat. 2014;145:785-90.
20. Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E. Statin use and breast cancer survival: a nationwide cohort study from Finland. PLoS One. 2014;9:e110231.
21. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, et al. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol. 2008;109:418-25.
22. Vinson GP, Barker S, Puddefoot JR. The renin-angiotensin system in the breast and breast cancer. Endocr Relat Cancer. 2012;19:R1-R19.
23. Rostoker R, Abelson S, Bitton-Worms K, Genkin I, Ben-Shmuel S, Dakwar M, et al. Highly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer. 2015;22:145-57.
24. Tseng CH. Use of insulin and mortality from breast cancer among Taiwanese women with diabetes. J Diabetes Res. 2015;2015:678756.
25. Tseng CH. Insulin use and smoking jointly increase the risk of bladder cancer mortality in patients with type 2 diabetes. Clin Genitourin Cancer. 2013;11:508-14.
26. Tseng CH. Type 2 diabetes, smoking, insulin use and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan. Hepatol Int. 2013;7:693-702.
27. Miele L, Bosetti C, Turati F, Rapaccini G, Gasbarrini A, La Vecchia C, et al. Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk. Gastroenterol Res Pract. 2015;2015:570356.
28. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55:948-58.
29. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009;52:2499-506.
30. Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, et al. Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol. 2014;184:2099-110.
31. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094-8.
32. Printz C. Researchers find link between high cholesterol and breast cancer. Cancer. 2014;120:3429.
33. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461-8.
34. Bonovas S, Lytras T, Sitaras NM. Statin use and breast cancer: do we need more evidence and what should this be? Expert Opin Drug Saf. 2014;13:271-5.
35. Devore EE, Kim S, Ramin CA, Wegrzyn LR, Massa J, Holmes MD, et al. Antihypertensive medication use and incident breast cancer in women. Breast Cancer Res Treat. 2015;150:219-29.
36. Leung HW, Hung LL, Chan AL, Mou CH. Long-term use of antihypertensive agents and risk of breast cancer: a population-based case-control study. Cardiol Ther. 2015;4:65-76.
37. Lee HH, Tsan YT, Ho WC, Lin MH, Lee CH, Tseng CD, et al. Health Data Analysis in Taiwan (hDATa) Research Group. Angiotensin-converting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide case-control study. J Hypertens. 2012;30:2432-9.
38. Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, et al. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON. 2015;20:50-6.
39. Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74years. JAMA Intern Med. 2013;173:1629-37.
40. Namiranian N, Moradi-Lakeh M, Razavi-Ratki SK, Doayie M, Nojomi M. Risk factors of breast cancer in the Eastern Mediterranean Region: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15:9535-41.
41. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137:307-14.
42. Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014;144:1-10.
43. Tseng CH. Body mass index and blood pressure in adult type 2 diabetic patients in Taiwan. Circ J. 2007;71:1749-54.
44. van Stralen KJ, Dekker FW, Zoccali C, Jager KJ. Confounding. Nephron Clin Pract. 2010;116:c143-7.
45. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003;22:61-76.
46. Bureau of Health Promotion. Cancer Registry Annual Report 2007. Taiwan: Department of Health, Executive Yuan; 2010.